Strategies to improve radiotherapy with targeted drugs

Nature Reviews Cancer

Volumn 11, Issue 4, 2011, Pages 239-253

  Begg, Adrian C ^a   Stewart, Fiona A ^a   Vens, Conchita ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; HEMOPOIETIC GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KERATINOCYTE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PALIFERMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TOLL LIKE RECEPTOR 5; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ANGIOGENESIS; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL HYPOXIA; CELL KILLING; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG TARGETING; EXCISION REPAIR; FANCONI ANEMIA; HOMOLOGOUS RECOMBINATION; HUMAN; IONIZING RADIATION; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; TISSUE INJURY; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; WHOLE BODY RADIATION;

HUMANS; NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 79953054421     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3007     Document Type: Review

References (191)

1. Delaney, G., Jacob, S., Featherstone, C. & Barton, M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104, 1129-1137 (2005). (Pubitemid 41278947)
2. Hoppe, R, Phillips, T. L. & Roach, M. Leibel and Phillips Textbook of Radiation Oncology Third Edition (Elsevier, 2010).
3. Bhide, S. A. & Nutting, C. M. Recent advances in radiotherapy. BMC Med. 8, 25 (2010).
4. Nordsmark, M. et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77, 18-24 (2005). (Pubitemid 41503384)
5. Kim, J. J. & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature Rev. Cancer 5, 516-525 (2005). (Pubitemid 40942828)
6. Withers, H. R., Taylor, J. M. & Maciejewski, B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27, 131-146 (1988).
7. West, C. M., Davidson, S. E., Roberts, S. A. & Hunter, R. D. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br. J. Cancer 68, 819-823 (1993). (Pubitemid 23301293)
8. Ahn, G. O. et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl Acad. Sci. USA 107, 8363-8368 (2010).
9. Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694-705 (2010).
10. Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071-1078 (2009).
11. Kastan, M. B. DNA damage responses: mechanisms and roles in human disease: 2007 G. H.-A. Clowes Memorial Award Lecture. Mol. Cancer Res. 6, 517-524 (2008).
12. Lobrich, M. & Jeggo, P. A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nature Rev. Cancer 7, 861-869 (2007). (Pubitemid 350006255)
13. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability-an evolving hallmark of cancer. Nature Rev. Mol. Cell Biol. 11, 220-228 (2010).
14. Bartkova, J. et al. ATM activation in normal human tissues and testicular cancer. Cell Cycle 4, 838-845 (2005). (Pubitemid 41353838)
15. Jeggo, P. & Lavin, M. F. Cellular radiosensitivity: how much better do we understand it? Int. J. Radiat. Biol. 85, 1061-1081 (2009).
16. O'Driscoll, M. & Jeggo, P. A. The role of double-strand break repair - insights from human genetics. Nature Rev. Genet. 7, 45-54 (2006). (Pubitemid 41828947)
17. Almeida, K. H. & Sobol, R. W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst). 6, 695-711 (2007). (Pubitemid 46670095)
18. Caldecott, K. W. Single-strand break repair and genetic disease. Nature Rev. Genet. 9, 619-631 (2008).
19. Dianov, G. L., O'Neill, P. & Goodhead, D. T. Securing genome stability by orchestrating DNA repair: removal of radiation-induced clustered lesions in DNA. Bioessays 23, 745-749 (2001). (Pubitemid 32792519)
20. Jenner, T. J., Fulford, J. & O'Neill, P. Contribution of base lesions to radiation-induced clustered DNA damage: implication for models of radiation response. Radiat. Res. 156, 590-593 (2001). (Pubitemid 33027533)
21. Veuger, S. J., Curtin, N. J., Richardson, C. J., Smith, G. C. & Durkacz, B. W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 63, 6008-6015 (2003). (Pubitemid 37187504)
22. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004). (Pubitemid 39665530)
23. Rainey, M. D., Charlton, M. E., Stanton, R. V. & Kastan, M. B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 68, 7466-7474 (2008).
24. Chalmers, A. J., Lakshman, M., Chan, N. & Bristow,-R. G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin. Radiat. Oncol. 20, 274-281 (2010).
25. Noel, G. et al. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther. 5, 564-574 (2006).
26. Dungey, F. A., Loser, D. A. & Chalmers, A. J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72, 1188-1197 (2008).
27. Calabrese, C. R. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96, 56-67 (2004).
28. Albert, J. M. et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13, 3033-3042 (2007). (Pubitemid 46849580)
29. Verheij, M., Vens, C. & van Triest, B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist. Updat. 13, 29-43 (2010).
30. Simeonov, A. et al. Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS One 4, e5740 (2009).
31. Abbotts, R. & Madhusudan, S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev. 36, 425-435 (2010).
32. Higgins, G. S. et al. A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res. 70, 2984-2993 (2010).
33. Higgins, G. S. et al. Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget. 1, 175-184 (2010).
34. Lemee, F. et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc. Natl Acad. Sci. USA 107, 13390-13395 (2010).
35. Mukherjee, B. et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 69, 4252-4259 (2009).
36. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nature Rev. Cancer 8, 193-204 (2008). (Pubitemid 351301852)
37. Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689-698 (2005). (Pubitemid 41486362)
38. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). (Pubitemid 40559005)
39. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
40. Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 117, 1440-1449 (2007). (Pubitemid 46718432)
41. Williamson, C. T. et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 9, 347-357 (2010).
42. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006). (Pubitemid 44299177)
43. Vens, C. & Begg, A. C. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin. Radiat. Oncol. 20, 241-249 (2010).
44. Neijenhuis, S., Verwijs-Janssen, M., van den Broek, L. J., Begg, A. C. & Vens, C. Targeted radiosensitization of cells expressing truncated DNA Polymerase β. Cancer Res. 70, 8706-8714 (2010).
45. Bristow, R. G. & Hill, R. P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Rev. Cancer 8, 180-192 (2008). (Pubitemid 351301853)
46. Chan, N. et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68, 605-614 (2008). (Pubitemid 351380090)
47. Bindra, R. S. et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 65, 11597-11604 (2005). (Pubitemid 41821719)
48. Bindra, R. S. et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell Biol. 24, 8504-8518 (2004). (Pubitemid 39245072)
49. McEllin, B. et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457-5464 (2010).
50. Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
51. Dedes, K. J. et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2, 53ra75 (2010).
52. Nitta, M. et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS ONE 5, e10767 (2010).
53. Wouters, B. G., Giaccia, A. J., Denko, N. C. & Brown, J. M. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 57, 4703-4706 (1997). (Pubitemid 27468970)
54. Slichenmyer, W. J., Nelson, W. G., Slebos, R. J. & Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53, 4164-4168 (1993). (Pubitemid 24146760)
55. Bucher, N. & Britten, C. D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 98, 523-528 (2008). (Pubitemid 351214533)
56. Mack, P. C. et al. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat. Res. 162, 623-634 (2004).
57. Syljuasen, R. G. et al. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res. 64, 9035-9040 (2004). (Pubitemid 39665514)
58. O'Connor, M. J., Martin, N. M. & Smith, G. C. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26, 7816-7824 (2007). (Pubitemid 350242461)
59. Zabludoff, S. D. et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7, 2955-2966 (2008).
60. Morgan, M. A. et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70, 4972-4981 (2010).
61. Boutros, R., Lobjois, V. & Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature Rev. Cancer 7, 495-507 (2007). (Pubitemid 46985396)
62. Brezak, M. C., Kasprzyk, P. G., Galcera, M. O., Lavergne, O. & Prevost, G. P. CDC25 inhibitors as anticancer agents are moving forward. Anticancer Agents Med. Chem. 8, 857-862 (2008).
63. Golding, S. E. et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 8, 2894-2902 (2009).
64. Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T. & D'Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 8, 24 (2009).
65. Kirshner, J. et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 66, 10861-10869 (2006). (Pubitemid 44876983)
66. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
67. LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32-50 (2008).
68. Kim, I. A. et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 65, 7902-7910 (2005).
69. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N.-Engl. J. Med. 354, 567-578 (2006). (Pubitemid 43209104)
70. Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28 (2010).
71. Bianco, C. et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8, 3250-3258 (2002). (Pubitemid 35155038)
72. Feng, F. Y. et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin. Cancer Res. 13, 2512-2518 (2007). (Pubitemid 46698604)
73. Krause, M., Gurtner, K., Deuse, Y. & Baumann, M. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int. J. Radiat. Biol. 85, 943-954 (2009).
74. Russo, S. M. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 50, 183-193 (2001).
75. Li, F. & Sethi, G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta. 1805, 167-180 (2010).
76. Nakanishi, C. & Toi, M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nature Rev. Cancer. 5, 297-309 (2005). (Pubitemid 40488635)
77. Veuger, S. J., Hunter, J. E. & Durkacz, B. W. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene 28, 832-842 (2009).
78. Tsuboi, Y. et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. J.-Neurosurg. 110, 594-604 (2009).
79. Sandur, S. K. et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int. J. Radiat. Oncol. Biol. Phys. 75, 534-542 (2009).
80. Golding, S. E. et al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 67, 1046-1053 (2007).
81. Kriegs, M. et al. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst). 9, 889-897 (2010).
82. Andarawewa, K. L., Paupert, J., Pal, A. & Barcellos-Hoff, M. H. New rationales for using TGFbeta inhibitors in radiotherapy. Int. J. Radiat. Biol. 83, 803-811 (2007). (Pubitemid 350219100)
83. Wiegman, E. M., Blaese, M. A., Loeffler, H., Coppes, R. P. & Rodemann, H. P. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother. Oncol. 83, 289-295 (2007). (Pubitemid 46907986)
84. Dent, P., Yacoub, A., Fisher, P. B., Hagan, M. P. & Grant, S. MAPK pathways in radiation responses. Oncogene 22, 5885-5896 (2003). (Pubitemid 37176709)
85. Beg, A. A. & Baltimore, D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274, 782-784 (1996). (Pubitemid 26398258)
86. Brown, J. M. & Attardi, L. D. The role of apoptosis in cancer development and treatment response. Nature Rev. Cancer 5, 231-237 (2005). (Pubitemid 40314954)
87. Toulany, M. et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin. Cancer Res. 12, 4119-4126 (2006). (Pubitemid 44078101)
88. Dittmann, K. et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J.-Biol. Chem. 280, 31182-31189 (2005). (Pubitemid 41291855)
89. Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225-239 (2007). (Pubitemid 47101660)
90. Wouters, B. G. & Brown, J. M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 147, 541-550 (1997). (Pubitemid 27204090)
91. Tredan, O., Galmarini, C. M., Patel, K. & Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99, 1441-1454 (2007).
92. Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510-5514 (1995).
93. Rouschop, K. M. & Wouters, B. G. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr. Mol. Med. 9, 417-424 (2009).
94. Chi, J. T. et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3, e47 (2006).
95. Winter, S. C. et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 67, 3441-3449 (2007). (Pubitemid 46724885)
96. Seigneuric, R. et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother. Oncol. 83, 374-382 (2007). (Pubitemid 46915549)
97. Kjellen, E., Joiner, M. C., Collier, J. M., Johns, H. & Rojas, A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol. 22, 81-91 (1991).
98. Kaanders, J. H., Bussink, J. & van der Kogel, A. J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 3, 728-737 (2002). (Pubitemid 35446742)
99. Dische, S., Rojas, A., Rugg, T., Hong, A. & Michael, B. D. Carbogen breathing: a system for use in man. Br. J. Radiol. 65, 87-90 (1992).
100. Kaanders, J. H. & van der Maazen, R. W. A convenient and reliable method for carbogen breathing in man. Radiother. Oncol. 29, 341-343 (1993). (Pubitemid 24025356)
101. Khandelwal, S. R. et al. Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am. J.-Physiol. 265, H1450-H1453 (1993). (Pubitemid 23327742)
102. Amorino, G. P. et al. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. Radiat. Res. 156, 294-300 (2001). (Pubitemid 32801098)
103. Scott, C., Suh, J., Stea, B., Nabid, A. & Hackman, J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am. J. Clin. Oncol. 30, 580-587 (2007). (Pubitemid 350307182)
104. Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother. Oncol. 46, 135-146 (1998). (Pubitemid 28109172)
105. Brown, J. M., Diehn, M. & Loo, B. W. Jr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 78, 323-327 (2010).
106. Brown, J. M. & Koong, A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl. Cancer Inst. 83, 178-185 (1991).
107. Rischin, D. et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 28, 2989-2995 (2010).
108. Hicks, K. O. et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16, 4946-4957 (2010).
109. Rouschop, K. M. et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Invest. 120, 127-141 (2010).
110. Qayum, N. et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 69, 6347-6354 (2009).
111. Cohen-Jonathan, E. et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. 61, 2289-2293 (2001). (Pubitemid 32692061)
112. Carmeliet, P. et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998). (Pubitemid 28373960)
113. Ahn, G. O. & Brown, J. M. Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle. 8, 970-976 (2009).
114. Ahn, G. O. & Brown, J. M. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis. 12, 159-164 (2009).
115. Ahn, G. O. & Brown, J. M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193-205 (2008). (Pubitemid 351318369)
116. Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003). (Pubitemid 36583102)
117. Stone, H. B. et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat. Res. 162, 711-728 (2004). (Pubitemid 39552901)
118. Patt, H. M., Tyree, E. B., Straube, R. L. & Smith, D. E. Cysteine protection against X irradiation. Science 110, 213-214 (1949).
119. Weiss, J. F. & Landauer, M. R. History and development of radiation-protective agents. Int. J. Radiat. Biol. 85, 539-573 (2009).
120. Denekamp, J., Michael, B. D., Rojas, A. & Stewart, F. A. Radioprotection of mouse skin by WR-2721: the critical influence of oxygen tension. Int. J. Radiat. Oncol. Biol. Phys. 8, 531-534 (1982). (Pubitemid 12090574)
121. Hensley, M. L. et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27, 127-145 (2009).
122. Antonadou, D. et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 57, 402-408 (2003). (Pubitemid 37040936)
123. Komaki, R. et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 58, 1369-1377 (2004). (Pubitemid 38438296)
124. Andreassen, C. N., Grau, C. & Lindegaard, J. C. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol. 13, 62-72 (2003). (Pubitemid 36173261)
125. Dorr, W., Heider, K. & Spekl, K. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int. J. Radiat. Biol. 81, 557-565 (2005). (Pubitemid 41784877)
126. Farrell, C. L. et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 58, 933-939 (1998). (Pubitemid 28182461)
127. Khan, W. B., Shui, C., Ning, S. & Knox, S. J. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat. Res. 148, 248-253 (1997). (Pubitemid 27374102)
128. Chen, L. et al. The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int. J. Radiat. Oncol. Biol. Phys. 60, 1520-1529 (2004). (Pubitemid 39601870)
129. Spielberger, R. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N.-Engl. J.-Med. 351, 2590-2598 (2004). (Pubitemid 39628580)
130. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006). (Pubitemid 44387609)
131. Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737 (1999). (Pubitemid 29428873)
132. Burdelya, L. G. et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226-230 (2008). (Pubitemid 351521417)
133. Okunieff, P. et al. In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat. Res. 150, 204-211 (1998). (Pubitemid 28347981)
134. Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001). (Pubitemid 32694744)
135. Fuks, Z. et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 54, 2582-2590 (1994). (Pubitemid 24173742)
136. Schuller, B. W. et al. No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome. Int. J. Radiat. Oncol. Biol. Phys. 68, 205-210 (2007). (Pubitemid 46589862)
137. Potten, C. S. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat. Res. 161, 123-136 (2004). (Pubitemid 38129805)
138. Tee, P. G. & Travis, E. L. Basic fibroblast growth factor does not protect against classical radiation pneumonitis in two strains of mice. Cancer Res. 55, 298-302 (1995).
139. Kirsch, D. G. et al. p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis. Science 327, 593-596 (2010).
140. Hauer-Jensen, M., Wang, J. & Denham, J. W. Bowel injury: current and evolving management strategies. Semin. Radiat. Oncol. 13, 357-371 (2003). (Pubitemid 36962656)
141. Martin, M., Lefaix, J. & Delanian, S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47, 277-290 (2000). (Pubitemid 30236366)
142. Bentzen, S. M. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nature Rev. Cancer 6, 702-713 (2006). (Pubitemid 44286002)
143. Zheng, H., Wang, J., Koteliansky, V. E., Gotwals, P. J. & Hauer-Jensen, M. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 119, 1286-1296 (2000).
144. Anscher, M. S., Thrasher, B., Rabbani, Z., Teicher, B. & Vujaskovic, Z. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 65, 876-881 (2006). (Pubitemid 43795819)
145. Haydont, V. et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin. Cancer Res. 13, 5331-5340 (2007). (Pubitemid 47510357)
146. Verheij, M., Stewart, F. A., Oussoren, Y., Weening, J. J. & Dewit, L. Amelioration of radiation nephropathy by acetylsalicylic acid. Int. J. Radiat. Biol. 67, 587-596 (1995).
147. Wang, J. et al. Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine. Thromb. Haemost. 87, 122-128 (2002). (Pubitemid 34092586)
148. Wang, J. et al. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. J.-Thromb. Haemost. 2, 2027-2035 (2004). (Pubitemid 40192757)
149. Glantz, M. J. et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44, 2020-2027 (1994). (Pubitemid 24349499)
150. Ozturk, B., Egehan, I., Atavci, S. & Kitapci, M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 58, 213-219 (2004). (Pubitemid 38010355)
151. Hauer-Jensen, M., Fink, L. M. & Wang, J. Radiation injury and the protein C pathway. Crit. Care Med. 32, S325-S330 (2004).
152. Zhao, W. et al. Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. Int. J. Radiat. Oncol. Biol. Phys. 67, 6-9 (2007). (Pubitemid 44959517)
153. Williams, J. P. et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat. Res. 161, 560-567 (2004). (Pubitemid 40754225)
154. Wang, J. et al. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 68, 1483-1490 (2007). (Pubitemid 47176821)
155. Irwin, B. C. et al. Calcium channel blockers may radionsensitize patients to radiation proctitis while statins, NSAIDs may radioprotect: a case-control study. Gastroenterology Abstr. 130 (Suppl. 2), A-460 (2006).
156. Moulder, J. E., Fish., B. L. & Cohen, E. P. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr. Pharm. Des 13, 1317-1325 (2007). (Pubitemid 46746369)
157. Robbins, M. E. & Diz, D. I. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int. J. Radiat. Oncol. Biol. Phys. 64, 6-12 (2006). (Pubitemid 41831202)
158. Kim, J. H. et al. Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat. Res. 161, 137-142 (2004). (Pubitemid 38129806)
159. Cohen, E. P. et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int. J. Radiat. Oncol. Biol. Phys. 70, 1546-1551 (2008). (Pubitemid 351417757)
160. Wang, L. W. et al. Can. angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat. Res. 153, 405-410 (2000). (Pubitemid 30185393)
161. Kang, S. K. et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 57, 1056-1066 (2003). (Pubitemid 37324124)
162. Rabbani, Z. N. et al. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer 5, 59 (2005).
163. Zhang, X. et al. Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum. Gene Ther. 19, 820-826 (2008).
164. Lefaix, J. L. et al. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: an experimental study. Int. J. Radiat. Oncol. Biol. Phys. 35, 305-312 (1996).
165. Delanian, S. et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother. Oncol. 32, 12-20 (1994). (Pubitemid 24246759)
166. Delanian, S. & Lefaix, J. L. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin. Radiat. Oncol. 17, 99-107 (2007). (Pubitemid 46476864)
167. Vujaskovic, Z. et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 33, 857-863 (2002). (Pubitemid 35232320)
168. Delanian, S., Porcher, R., Balla-Mekias, S. & Lefaix, J. L. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J. Clin. Oncol. 21, 2545-2550 (2003). (Pubitemid 46606336)
169. Delanian, S., Chatel, C., Porcher, R., Depondt, J. & Lefaix, J. L. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a Pentoxifylline-Tocopherol-Clodronate Combination (PENTOCLO): a Phase II Trial. Int. J. Radiat. Oncol. Biol. Phys. 16-Jul 2010 (doi: 10.1016/j.ijrobp.2010.03.0290
170. Dong, C. & Goldschmidt-Clermont, P. J. Endothelial progenitor cells: a promising therapeutic alternative for cardiovascular disease. J.-Interv. Cardiol. 20, 93-99 (2007). (Pubitemid 46457444)
171. Young, P. P., Vaughan, D. E. & Hatzopoulos, A. K. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog. Cardiovasc. Dis. 49, 421-429 (2007). (Pubitemid 46693946)
172. Mummery, C. L., Davis, R. P. & Krieger, J. E. Challenges in using stem cells for cardiac repair. Sci. Transl. Med. 2, 27ps17 (2010).
173. Coppes, R. P., van der Goot, A. & Lombaert, I. M. Stem cell therapy to reduce radiation-induced normal tissue damage. Semin. Radiat. Oncol. 19, 112-121 (2009).
174. Epperly, M. W. et al. Bone marrow origin of cells with capacity for homing and differentiation to esophageal squamous epithelium. Radiat. Res. 162, 233-240 (2004). (Pubitemid 39295423)
175. Lombaert, I. M. et al. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin. Cancer Res. 12, 1804-1812 (2006).
176. Lombaert, I. M. et al. Cytokine treatment improves parenchymal and vascular damage of salivary glands after irradiation. Clin. Cancer Res. 14, 7741-7750 (2008).
177. Francois, S. et al. Human mesenchymal stem cells favour healing of the cutaneous radiation syndrome in a xenogenic transplant model. Ann. Hematol. 86, 1-8 (2007). (Pubitemid 46138311)
178. Semont, A. et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 17, 952-961 (2010).
179. Lataillade, J. J. et al. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen. Med. 2, 785-794 (2007). (Pubitemid 47554832)
180. Lombaert, I. M. et al. Rescue of salivary gland function after stem cell transplantation in irradiated glands. PLoS ONE 3, e2063 (2008).
181. Rezvani, M. et al. Modification of radiation myelopathy by the transplantation of neural stem cells in the rat. Radiat. Res. 156, 408-412 (2001). (Pubitemid 32904994)
182. Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998). (Pubitemid 28193601)
183. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N.-Engl. J.-Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
184. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N.-Engl. J.-Med. 359, 1757-1765 (2008).
185. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N.-Engl. J.-Med. 360, 790-800 (2009).
186. International network of cancer genome projects. Nature 464, 993-998 (2010).
187. Kim, T. J. et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br. J. Cancer. 94, 1678-1682 (2006).
188. Gupta, A. K. et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8, 885-892 (2002). (Pubitemid 34742122)
189. Willers, H. et al. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol. Cancer Res. 7, 1304-1309 (2009).
190. Bentzen, S. M. Radiobiological considerations in the design of clinical trials. Radiother. Oncol. 32, 1-11 (1994).
191. Diez, P., Vogelius, I. S. & Bentzen, S. M. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 77, 1066-1071 (2010).